R&D Advances in immunosuppression research may bring transplant ... There has been little innovation in immunosuppression therapy for organ transplant patients over the past 30 years.
News Biogen races into phase 3 with Spinraza follow-up Biogen is looking to the future of its spinal muscular atrophy (SMA) business, taking a candidate offering once-yearly dosing into phase 3.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
